[EN] AMINO-HETEROARYL 7-HYDROXY-SPIROPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR<br/>[FR] ANTAGONISTES D'AMINO-HÉTÉROARYLE 7-HYDROXYSPIROPIPÉRIDINE INDOLINYLE DU RÉCEPTEUR P2Y1
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2014022253A1
公开(公告)日:2014-02-06
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor which may be used as medicaments.
[EN] SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY<br/>[FR] DÉRIVÉS D'OXINDOLE SPIRO-SUBSTITUÉS AYANT UNE ACTIVITÉ SUR AMPK
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2014202580A1
公开(公告)日:2014-12-24
The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Sulfonamide peri-substituted bicyclics for occlusive artery disease
申请人:Singh Jasbir
公开号:US20060079520A1
公开(公告)日:2006-04-13
Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula
A representative example is:
[EN] PROTEASOME ACTIVITY ENHANCING COMPOUNDS<br/>[FR] COMPOSÉS RENFORÇANT L'ACTIVITÉ DES PROTÉASOMES
申请人:PROTEOSTASIS THERAPEUTICS INC
公开号:WO2015073528A1
公开(公告)日:2015-05-21
The present invention is directed to compounds having the Formula (I), (II), (III), (IV), and (V), compositions thereof, the methods of synthesis of the compouds of interest, and to methods for the treatment of a condition associated with a dysfunction in proteostasis, such as cancer, inflammatory conditions, neurodegeneration, metabolic conditions, comprising administering an effective amount of a compound of the invention.
[EN] (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS<br/>[FR] COMPOSÉS (HÉTÉRO)ARYLE CYCLOPROPYLAMINES EN TANT QU'INHIBITEURS DE LSD1
申请人:ORYZON GENOMICS SA
公开号:WO2013057320A1
公开(公告)日:2013-04-25
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.